| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0735-1097(99)00608-7 |
| P698 | PubMed publication ID | 10716471 |
| P2093 | author name string | Stevenson LW | |
| Domanski MJ | |||
| Greenberg B | |||
| Dries DL | |||
| Exner DV | |||
| P2860 | cites work | Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group | Q33157410 |
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies | Q38508613 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy | Q44538339 | ||
| Heart failure in Nigerian hypertensive patients: the role of renal dysfunction. | Q50664524 | ||
| Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction | Q68525304 | ||
| The effect of diltiazem on mortality and reinfarction after myocardial infarction | Q69921762 | ||
| Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction | Q70743359 | ||
| Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms | Q72020066 | ||
| Interobserver discordance in the classification of mechanisms of death in studies of heart failure | Q74011068 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| systole | Q496359 | ||
| P304 | page(s) | 681-689 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. | |
| P478 | volume | 35 |
| Q46514949 | A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin |
| Q53591921 | A prognostic index for risk stratification for acute heart failure and death in subjects with ischemic cardiomyopathy and cardiac defibrillator. |
| Q48475700 | A prospective evaluation of nesiritide in the treatment of pediatric heart failure |
| Q37988380 | A rational approach to assess volume status in patients with decompensated heart failure |
| Q36407790 | A review of homocysteine and heart failure |
| Q39172578 | Abnormalities in serum biomarkers correlate with lower cardiac index in the Fontan population |
| Q55002696 | Acute Heart Failure Management. |
| Q36947421 | Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure |
| Q36814875 | Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy |
| Q37744472 | Acute kidney injury in patients with decompensated heart failure |
| Q35151913 | Adenosine and kidney function: potential implications in patients with heart failure |
| Q28253255 | Adenosine receptors and the kidney |
| Q64959122 | Adiponectin is valuable in the diagnosis of acute heart failure with renal insufficiency. |
| Q44416261 | Adma: a critical cardio‐renal link in heart failure? |
| Q37831838 | Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome |
| Q50193224 | An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best? |
| Q35770879 | Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function |
| Q37390747 | Anemia and chronic heart failure: from pathophysiologic mechanisms to clinical trial designs |
| Q33235437 | Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients |
| Q36203102 | Anemia and heart failure |
| Q44391152 | Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure |
| Q37930478 | Animal models of cardiorenal syndrome: a review. |
| Q37721628 | Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medi |
| Q50894580 | Assessing glomerular filtration rate in patients with severe heart failure: comparison between creatinine-based formulas. |
| Q84711425 | Association between deteriorated renal function and long-term clinical outcomes after percutaneous coronary intervention |
| Q37496070 | Association between kidney function and Framingham global cardiovascular disease risk score: a Chinese longitudinal study |
| Q37127236 | Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure |
| Q37500020 | Associations Between Neutrophil Gelatinase Associated Lipocalin, Neutrophil-to-Lymphocyte Ratio, Atrial Fibrillation and Renal Dysfunction in Chronic Heart Failure |
| Q35566139 | B-type natriuretic peptide and renal disease |
| Q35987052 | BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases |
| Q34080388 | Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis |
| Q39127729 | Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. |
| Q38626779 | Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure |
| Q43288643 | Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). |
| Q38063294 | Cardiac resynchronization therapy for prevention of heart failure events in elderly patients with left ventricular dysfunction |
| Q30497515 | Cardiac resynchronization therapy guided by cardiovascular magnetic resonance |
| Q37280350 | Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate |
| Q35055236 | Cardiac resynchronization therapy in the cardiorenal syndrome |
| Q42434368 | Cardio-renal anemia syndrome. |
| Q37913110 | Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially |
| Q33728260 | Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative |
| Q43232841 | Cardiorenal Resynchronization Therapy: Strengthening the Heart and Kidneys |
| Q38046441 | Cardiorenal [corrected] syndrome: an emerging problem in pediatric critical care |
| Q36245164 | Cardiorenal disease: a clinical intersection |
| Q37590475 | Cardiorenal syndrome in children with heart failure |
| Q36203074 | Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications |
| Q27023089 | Cardiorenal syndrome: a cardiologist's perspective of pathophysiology |
| Q38218395 | Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins |
| Q38068097 | Cardiorenal syndrome: pathophysiology and potential targets for clinical management |
| Q37947677 | Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins. |
| Q37696360 | Cardiorenal syndrome: still not a defined entity |
| Q26830674 | Cardiorenal syndrome: the emerging role of protein-bound uremic toxins |
| Q43871219 | Cardiorenal versus renocardiac syndrome: is there a difference? |
| Q37106407 | Cardiovascular implications of chronic kidney disease in older adults |
| Q37557361 | Cardiovascular risk factors in patients with chronic kidney disease |
| Q50585584 | Change in plasma volume and prognosis in acute decompensated heart failure: an observational cohort study. |
| Q34380235 | Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. |
| Q37804571 | Chronic kidney disease and heart failure—Bidirectional close link and common therapeutic goal |
| Q57414635 | Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population |
| Q33511547 | Chronic kidney disease increases cardiovascular unfavourable outcomes in outpatients with heart failure |
| Q30359729 | Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. |
| Q38152289 | Circulating biomarkers in patients with heart failure and preserved ejection fraction |
| Q44647047 | Clinical and Exercise Test Determinants of Survival After Cardiac Transplantation * |
| Q40586285 | Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure |
| Q36075516 | Clinical characteristics and echocardiographic features of black men vs. black women with systolic heart failure. |
| Q90325789 | Clinical impacts of changes of renal function during hospitalization depend on grades of renal dysfunction in acute decompensated heart failure |
| Q46121161 | Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure |
| Q35580130 | Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure |
| Q38632059 | Community burden and prognostic impact of reduced kidney function among patients hospitalized with acute decompensated heart failure: The Atherosclerosis Risk in Communities (ARIC) Study Community Surveillance |
| Q36551356 | Comorbid Heart Failure and Renal Impairment: Epidemiology and Management |
| Q34017388 | Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease |
| Q37878418 | Current and novel renal biomarkers in heart failure |
| Q46157359 | Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study |
| Q36482365 | Cystatin C concentration as a predictor of systolic and diastolic heart failure |
| Q36345739 | Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events |
| Q51749328 | Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. |
| Q35179503 | Demographics and concomitant disorders in heart failure |
| Q36954799 | Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. |
| Q43857252 | Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment |
| Q37328000 | Development and validation of a clinical index to predict survival after cardiac resynchronisation therapy |
| Q44472997 | Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality |
| Q36131123 | Diastolic Heart Failure Predicted by Left Atrial Expansion Index in Patients with Severe Diastolic Dysfunction |
| Q51958627 | Difference in long-term prognostic value of renal function between ischemic and non-ischemic mild heart failure. |
| Q34485114 | Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. |
| Q41968416 | Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling |
| Q30361766 | Effect of renal function on prognosis in chronic heart failure. |
| Q34020768 | Effectiveness of β-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease. |
| Q28212766 | Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure |
| Q37312535 | Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial |
| Q37688147 | Efficacy and safety of nesiritide in patients with acute decompensated heart failure. |
| Q46624916 | Elevated serum creatinine at baseline predicts poor outcome in patients receiving cardiac resynchronization therapy |
| Q37698861 | Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference |
| Q36555238 | Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors |
| Q35553282 | Erythropoietin should be part of congestive heart failure management |
| Q92458947 | Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology |
| Q35950332 | Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection |
| Q43610045 | Functional response to cardiac resynchronization therapy in patients with renal dysfunction and subsequent long-term mortality. |
| Q51462051 | Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. |
| Q42914818 | Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function |
| Q92925812 | Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations |
| Q40098944 | Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function |
| Q73816206 | Heart failure in a multiethnic population in Kuala Lumpur, Malaysia |
| Q46398793 | Heart failure in diabetes mellitus: clinical features and prognostic implications |
| Q44635339 | Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure |
| Q89983044 | Histamine provides an original vista on cardiorenal syndrome |
| Q37027541 | Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review |
| Q33693243 | Hypothyroidism and renal function in patients with systolic heart failure |
| Q42870341 | Impact of Worsening Renal Function During Hospital Admission on Resource Utilization in Patients With Heart Failure |
| Q80106802 | Impact of anemia on nonfatal coronary events after percutaneous coronary interventions |
| Q42265979 | Impact of baseline renal function on all-cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and meta-analysis. |
| Q47818966 | Impact of functional tricuspid regurgitation on heart failure and death in patients with functional mitral regurgitation and left ventricular dysfunction |
| Q87644784 | Impact of onset time of acute kidney injury on outcomes in patients with acute decompensated heart failure |
| Q61816562 | Impact of renal dysfunction on the management and outcome of acute heart failure: results from the French prospective, multicentre, DeFSSICA survey |
| Q35432267 | Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials. |
| Q44744709 | Ischemic mitral regurgitation and non-ST-segment elevation acute myocardial infarction: long-term prognosis. |
| Q41686228 | Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. |
| Q43722418 | Left atrial expansion index predicts all-cause mortality and heart failure admissions in dyspnoea |
| Q51595558 | Left atrial work in patients with stable chronic heart failure: factors associated and prognostic role. |
| Q78899068 | Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community |
| Q37279759 | Long-term survival of chronic dialysis patients following survival from an episode of multiple-organ failure |
| Q37033137 | Low albumin levels and high impedance ratio as risk factors for worsening kidney function during hospitalization of decompensated heart failure patients |
| Q37490581 | Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings |
| Q42824239 | Management of Anemia and Iron Deficiency in Heart Failure |
| Q37590471 | Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome |
| Q33797640 | Managing anemia in patients with chronic heart failure: what do we know? |
| Q34595173 | Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. |
| Q44583585 | Mild renal insufficiency and risk of congestive heart failure in men and women > or =70 years of age. |
| Q40377138 | Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy |
| Q46829296 | Mortality prediction using CHADS2/CHA2DS2-VASc/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation |
| Q24794480 | Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design |
| Q36317213 | Natriuretic peptides: novel therapeutic targets in heart failure |
| Q44392374 | Neurohumoral activity, heart failure and prognosis in patients with end-stage renal disease treated by hemodialysis |
| Q37108098 | New cardioprotective agent K201 is natriuretic and glomerular filtration rate enhancing |
| Q37531314 | Noncardiac comorbidities and acute heart failure patients. |
| Q34625223 | Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction |
| Q39396838 | Novel Endpoints for Heart Failure Clinical Trials |
| Q26822738 | Organ-specific responses to circulatory disturbances in heart failure: new insights |
| Q38586834 | Pathophysiology and clinical evaluation of acute heart failure |
| Q35164124 | Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators |
| Q36652795 | Plasma metabolomic profiles in different stages of CKD. |
| Q51055267 | Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. |
| Q44225713 | Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure |
| Q34437117 | Predictors of heart failure in patients with stable coronary artery disease: a PEACE study |
| Q44532755 | Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction |
| Q35788963 | Predictors of re-hospitalization in patients with chronic heart failure |
| Q43552499 | Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). |
| Q36517260 | Prevalence and prognostic impact of kidney disease on heart failure patients |
| Q57631051 | Prevention of heart failure |
| Q90674365 | Prognostic Prediction of Cardiopulmonary Exercise Test Parameters in Heart Failure Patients with Atrial Fibrillation |
| Q97645467 | Prognostic Significance of Chronic Kidney Disease (CKD-EPI Equation) and Anemia in Patients with Chronic Heart Failure Secondary to Chagas Cardiomyopathy |
| Q41166002 | Prognostic Significance of Interleukin-34 (IL-34) in Patients With Chronic Heart Failure With or Without Renal Insufficiency |
| Q46729998 | Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients |
| Q35640412 | Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction |
| Q36950077 | Prognostic markers in heart failure--congestion, neurohormones, and the cardiorenal syndrome |
| Q36364556 | Prognostic role of cardiac power index in ambulatory patients with advanced heart failure |
| Q35128552 | Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial |
| Q31114587 | Prognostic value of ankle brachial index for future incident heart failure in patients without previous heart failure: data from the impressive predictive value of ankle brachial index for clinical long term outcome in patients with cardiovascular d |
| Q34771608 | Prognostic value of estimating functional capacity with the use of the duke activity status index in stable patients with chronic heart failure |
| Q84183405 | Prognostic value of glomerular filtration rate 1 year after heart transplantation |
| Q30235600 | Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some? |
| Q34962156 | Proteinuria: an underappreciated risk factor in cardiovascular disease |
| Q54684488 | Pseudonormal mitral filling pattern predicts hospital re-admission in patients with congestive heart failure |
| Q99630453 | Range of adiposity and cardiorenal syndrome |
| Q94556338 | Rapid clinical assessment of hemodynamic profiles and targeted treatment of patient with acutely decompensated heart failure |
| Q35790792 | Recent advances in natriuretic peptides in congestive heart failure |
| Q91793562 | Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2 |
| Q37240652 | Reduced Kidney Function Is Associated With Cardiometabolic Risk Factors, Prevalent and Predicted Risk of Cardiovascular Disease in Chinese Adults: Results From the REACTION Study |
| Q74587371 | Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction |
| Q33764626 | Reduction of Na/K-ATPase affects cardiac remodeling and increases c-kit cell abundance in partial nephrectomized mice. |
| Q58737866 | Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterization |
| Q42910207 | Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial—Cardiac Resynchronization Therapy (MADIT-CRT) |
| Q41686272 | Relation of Renal Function with Left Ventricular Systolic Function and NT-proBNP Level and Its Prognostic Implication in Heart Failure with Preserved versus Reduced Ejection Fraction: an analysis from the Korean Heart Failure (KorHF) Registry. |
| Q54601825 | Relationship of renal insufficiency and clinical features or comorbidities with clinical outcome in patients hospitalised for acute heart failure syndromes. |
| Q37356318 | Relaxin, a pleiotropic vasodilator for the treatment of heart failure. |
| Q35990837 | Renal Function in Relation to Cardiac (123)I-MIBG Scintigraphy in Patients with Chronic Heart Failure |
| Q40731837 | Renal Response in Patients with Chronic Kidney Disease Predicts Outcome Following Cardiac Resynchronization Therapy |
| Q34305164 | Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure |
| Q36077720 | Renal disease in cardiovascular disorders: an underrecognized problem |
| Q51181204 | Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. |
| Q37900203 | Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment |
| Q36773681 | Renal dysfunction in heart failure patients: what is the evidence? |
| Q51902181 | Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. |
| Q31145367 | Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up study |
| Q82414338 | Renal function and mortality following cardiac resynchronization therapy |
| Q33943876 | Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years |
| Q37238605 | Renal function predicts survival in patients with acute ischemic stroke |
| Q34459987 | Renal function: the Cinderella of cardiovascular risk profile |
| Q36667160 | Renal impairment predicts long-term mortality risk after acute myocardial infarction |
| Q36667145 | Renal insufficiency and mortality in patients with known or suspected coronary artery disease |
| Q49824369 | Response and outcomes of cardiac resynchronization therapy in patients with renal dysfunction |
| Q35106487 | Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics |
| Q49565170 | Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study |
| Q37870921 | Risk stratification and short-term prognosis in acute heart failure syndromes: a review of novel biomarkers |
| Q36050476 | Role of echocardiography in the contemporary management of chronic heart failure |
| Q38766189 | Role of imaging in the evaluation of renal dysfunction in heart failure patients. |
| Q34444804 | Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure |
| Q37322844 | Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome |
| Q45149761 | Sex-related bedside clinical variables associated with survival of older inpatients with heart failure |
| Q45141283 | Sex-specific acute heart failure phenotypes and outcomes from PROTECT. |
| Q46132135 | Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. |
| Q30235107 | Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy |
| Q50330068 | Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study |
| Q34388998 | Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease |
| Q44169479 | Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications |
| Q37073583 | Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring--further insights from SOLVD. |
| Q47803380 | The Kidney in Critical Cardiac Disease: Proceedings From the 10th International Conference of the Pediatric Cardiac Intensive Care Society |
| Q37078155 | The association between kidney function, coronary artery disease, and clinical outcome in patients undergoing coronary angiography |
| Q38755320 | The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction. |
| Q28208693 | The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations |
| Q37167806 | The cardiorenal connection in heart failure |
| Q36089093 | The cardiorenal syndrome: lessons from the ADHERE database and treatment options |
| Q34340391 | The cardiorenal syndrome: making the connection |
| Q35742923 | The effects of dose reduction of furosemide on glomerular filtration rate in stable systolic heart failure |
| Q34821510 | The impact of chronic kidney disease on the annual prognosis in patients 80+ years old suffering from chronic heart failure |
| Q46343713 | The impact of occult renal failure on the cardiovascular risk stratification in an elderly population: the PREV-ICTUS study |
| Q35737499 | The kidney in heart failure: an update |
| Q36564049 | The natural history of preclinical diastolic dysfunction: a population-based study |
| Q35105833 | The prognostic significance of renal dysfunction in patients with chronic systolic heart failure |
| Q44158707 | The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure |
| Q46468613 | The progressive cardiorenal syndrome in heart failure: mechanisms and therapeutic insights |
| Q37179961 | The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio |
| Q50790809 | The role of ultrafiltration in the management of heart failure. |
| Q34442587 | Therapeutic options for the management of the cardiorenal syndrome |
| Q95810354 | Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome |
| Q33973976 | Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome |
| Q37784234 | Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure |
| Q37140940 | Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches |
| Q46514937 | Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. |
| Q44476845 | Usefulness of creatinine clearance in predicting early and late death after primary angioplasty for acute myocardial infarction |
| Q36964715 | V2 receptor antagonism with tolvaptan in heart failure |
| Q37108078 | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| Q91631443 | Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome |
| Q35114953 | Worsening of renal function during 1 year after hospital discharge is a strong and independent predictor of all-cause mortality in acute decompensated heart failure |
| Q34354535 | Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions |
| Q46750124 | Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. |
| Q41216371 | Worsening renal function in patients hospitalized with acute heart failure: risk factors and prognostic significances |
| Q83879593 | [Anemia in chronic kidney disease and its cardiovascular implications] |
| Q83879580 | [Renal function in heart failure patients. Prognostic influence and therapeutic implications] |
| Q35081510 | β2-Microglobulin and TIMP1 Are Linked Together in Cardiorenal Remodeling and Failure |
Search more.